FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry, specifically to deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoromethyl)-phenyl]-1,2-dihydroquinoline-3-carboxamide. Invention also relates to a pharmaceutical composition based on deuterium-enriched carboxamide, method for production thereof and method of treating malignant hyperproliferative disorder or autoimmune disease, based on use of deuterium-enriched carboxamide.
EFFECT: technical result is obtaining deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoromethyl)-phenyl]-1,2-dihydroquinoline-3-carboxamide, having useful biological properties.
25 cl, 7 dwg, 10 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2450000C2 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2429237C2 |
| TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF ITS USE | 2020 |
|
RU2747991C1 |
| TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS FOR USE THEREOF | 2015 |
|
RU2715421C2 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| GSK-3 INHIBITORS | 2006 |
|
RU2449998C2 |
| 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2624493C2 |
| COMPOSITIONS AND METHODS WHICH CAN BE USED FOR TREATING PROLIFERATIVE DISEASES | 2015 |
|
RU2711500C2 |
| COMBINATION FOR TREATING PROSTATE CANCER, A PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATING | 2017 |
|
RU2733950C1 |
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION | 2016 |
|
RU2744897C2 |
